Chromocell Therapeutics Corporation — Form 10-Q Summary
Reporting period: Three months ended March 31, 2024, compared with the three months ended March 31, 2023. The provided filing identifies the registrant as Chromocell Therapeutics Corporation, not Pelthos Therapeutics Inc. The unaudited interim financial statements were prepared under U.S. GAAP.
Business Context
Chromocell is a clinical-stage biotechnology company developing non-opioid pain therapies targeting the NaV1.7 sodium ion channel. Its principal programs are CC8464 for neuropathic pain and CT2000, a topical formulation being developed for eye pain. The Company has not generated revenue from its intended operations and does not expect product revenue for several years.
On February 21, 2024, the Company completed an initial public offering of 1,100,000 shares at $6.00 per share and received approximately $5.7 million of net proceeds. A 9-for-1 reverse stock split became effective in February 2024; historical share and per-share information was retroactively adjusted.
Financial Results and Key Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No operating revenue |
| General and administrative expense | $787,561 | $477,630 | +65% |
| Research and development expense | $466,606 | $186,117 | +151% |
| Professional fees | $679,815 | $250,836 | +171% |
| Total operating expenses | $1,933,982 | $914,583 | +111% |
| Interest expense | $628,348 | $51,978 | +1,109% |
| Net loss | $2,562,330 | $966,561 | +165% |
| Basic and diluted loss per share | $0.55 | $0.87 | Loss per share decreased |
| Net cash used in operating activities | $1,991,893 | $173,369 | Higher cash burn |
| Net cash provided by financing activities | $5,665,731 | $166,903 | Primarily IPO proceeds in 2024 |
Balance sheet and liquidity: Cash was $3.77 million at March 31, 2024, compared with $96,391 at December 31, 2023. Working capital was approximately $1.1 million, compared with a working capital deficit of approximately $6.4 million at year-end 2023. Total liabilities were $2.90 million, and stockholders’ equity was $1.13 million, compared with a stockholders’ deficit of $6.44 million at December 31, 2023.
The Company had no long-term debt reported at March 31, 2024. Investor, director, and bridge notes were paid or converted into common stock in connection with the IPO. Interest expense included approximately $605,630 of debt-discount amortization, largely reflecting the conversion of debt at the IPO.
Operating cash use increased primarily because of the larger net loss, higher research and development spending, professional fees, and prepaid expenses. Financing cash flow primarily reflected $5.97 million of common-stock proceeds, partially offset by bridge-loan repayment and a stock rescission payment.
Material Changes Versus the Prior Comparable Period
- Operating expenses more than doubled, driven by higher public-company, audit, legal, marketing, compensation, and clinical-development costs.
- Research and development expense increased by $280,489, including $303,397 of chemistry, manufacturing, and controls costs.
- Professional fees increased by $428,979, primarily from IPO-readiness activities.
- Net loss increased by $1.60 million, while interest expense rose by $576,370 due substantially to debt-discount amortization upon debt conversion.
- Cash increased substantially following the IPO, but cash burn remained significant and the Company continued to report an accumulated deficit, which reached approximately $16.1 million.
- The Company issued 2,600 shares of Series C convertible redeemable preferred stock to Chromocell Holdings in exchange for the re-assumption of approximately $1.6 million of direct liabilities and waiver of a $0.6 million cash obligation.
Guidance, Outlook, Risks, and Unusual Items
- Management expects to continue incurring operating losses and negative operating cash flows for the foreseeable future. It estimates that IPO proceeds and existing cash may fund operations and capital expenditures through the end of 2024, but states that assumptions may be incorrect.
- The financial statements disclose substantial doubt about the Company’s ability to continue as a going concern for the twelve months following issuance. Additional financing may be required through equity, debt, strategic partnerships, grants, or other arrangements.
- A slow dose-escalation study for CC8464 is expected to begin dosing in the third quarter of 2024, with approximately 20 healthy volunteers and an anticipated total duration of approximately nine months. A Phase 2a proof-of-concept study is expected to launch in 2025.
- CT2000 ophthalmic toxicology work is expected to begin in the second half of 2024, with clinical trials for the ophthalmic formulation expected to start in 2025.
- The Company plans to begin development programs for licensed spray formulations in the third quarter of 2024, subject to regulatory discussions and additional development requirements.
- Prior Phase 1 studies involving 207 patients indicated overall tolerability but identified rashes in certain patients. The Company is evaluating whether slower dose escalation reduces this risk. Approval is not assured.
- A former executive has asserted wrongful termination and seeks $479,169; the Company had accrued $363,091 as of March 31, 2024 and believes the claim is without merit.
- The Company was named in an action involving the New Jersey Economic Development Authority and Chromocell Holdings concerning an alleged $510,701 rent-related obligation. The Company states that the matter concerns Chromocell Holdings, believes it was improperly named, and filed motions seeking dismissal.
- Disclosure controls and procedures were deemed ineffective as of March 31, 2024. Management identified material weaknesses involving segregation of duties, review controls, and information-technology general controls.
- As of March 31, 2024, the Company had deposits exceeding federally insured limits. It also had 197,560 stock options and 55,000 warrants excluded from diluted loss per share because their effects were anti-dilutive.
- After quarter-end, the Company documented $131,868 of unpaid consultant fees in a promissory note bearing 4.86% interest and entered into an employment agreement with its CEO providing for a $410,000 annualized salary and a $56,666 signing bonus.
Investor Verification Checklist
- Confirm the issuer identity and ticker because the supplied request names Pelthos Therapeutics Inc., while the filing names Chromocell Therapeutics Corporation and ticker CHRO.
- Assess the going-concern disclosure, projected cash runway, quarterly operating cash burn, and the probability and terms of additional financing.
- Review the IPO-related debt conversions, preferred-stock rights, warrants, options, and potential dilution from securities held by selling stockholders.
- Monitor CC8464 dose-escalation results, rash incidence, regulatory feedback, and the timing and funding of the planned Phase 2a study.
- Evaluate the CT2000 and licensed spray-formulation development plans, including regulatory, manufacturing, licensing, and royalty obligations.
- Track the former executive claim, the New Jersey EDA litigation, and any resulting cash requirements.
- Review remediation of the identified material weaknesses in disclosure controls and financial reporting.